Clinical Trial

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors combined with hormonal therapy are the current standard frontline treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER-2)-negative metastatic breast cancer (MBC). However, the optimal treatment after progression on CDK4/6 inhibitors remains unknown. Anlotinib is an oral multi-target tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. This study aimed to evaluate the safety and efficacy of anlotinib-based combination therapy in patients with HR+ MBC previously treated with a CDK4/6 inhibitor.
Trial Details
NCT Number NCT06734533
Lead Sponsor Hunan Cancer Hospital
Conditions HR+ Breast Cancer
Enrollment 80 participants
Start Date 2024-12-05
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-16